Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133673 | 0.83 | GRM5 (0.33) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1642606 | 0.79 | CDK8 (0.33) | ALDH1A1HPGDGRM5 | |
| SCHEMBL3250054 | 0.79 | ALDH1A1 (0.38) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2627822 | 0.79 | HPGD (0.53) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL25828301 | 0.76 | — | — | |
| SCHEMBL1690313 | 0.76 | CYP2D6 (0.40) | ALDH1A1KDM4EL3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL15723952 | 0.75 | ALOX5AP (0.38) | CYP2C19 | |
| SCHEMBL19769060 | 0.75 | NOS3 (0.31) | NOS3NOS2 | |
| SCHEMBL29993600 | 0.74 | — | — | |
| SCHEMBL4036995 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020198469-A1 | METHOD FOR TREATING EPIDERMAL GROWTH FACTOR RECEPTOR-DRIVEN CANCERS WITH PROTEIN KINASE C INHIBITORS IN COMBINATION WITH AN EGFR-TYROSINE KINASE INHIBITOR | IDEAYA BIOSCIENCES INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20130165473-A1 | Azaquinolinone Derivatives and Uses Thereof | ASTRAZENECA AB (SE) | 2013-06-27 | — | — | US | disclosed |
| US-8343996-B2 | Azaquinolinone derivatives and uses thereof | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-20100130540-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130540-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | TPMT, AZI2, NNMT | ALDH1A1 332/4885HPGD 512/4885SMN1; SMN2 130/4885 |
| US-20130165473-A1 | Azaquinolinone Derivatives and Uses Thereof | TPMT, AZI2, NNMT | ALDH1A1 332/4885HPGD 512/4885SMN1; SMN2 130/4885 |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CXCR4, CXCL12, CXCR1 | ALDH1A1 1506/4885HPGD 1346/4885SMN1; SMN2 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.